Johnson & Johnson, Merck, Bristol-Myers Squibb Upgraded

Johnson & Johnson, Merck, Bristol-Myers Squibb shares are on Jefferies' bullish radar

Mar 9, 2017 at 9:20 AM
facebook twitter linkedin


Analysts are weighing in big-cap drug stocks Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), and Bristol-Myers Squibb Co (NYSE:BMY). Here's a roundup of today's bullish brokerage notes on JNJ, MRK, and BMY shares.

Jefferies Predicts Record Highs for Johnson & Johnson

Jefferies raised its price target on JNJ to $132, representing record-high territory for the Dow stock, and a solid premium to Wednesday's close of $124.10. The shares have been rising in recent weeks, gaining 12% since their late-January low. There's plenty of room for additional bullish attention to come through on Johnson & Johnson, since 11 of 18 covering brokerage firms still rate the equity a "hold" or worse.

Fresh Price-Target Hike for Merck Stock

Jefferies also upped its price target on MRK, setting the bar at $52. However, there's still room to move, considering this new target is at a significant discount to last night's finish at $65.80. Merck & Co., Inc. has had a strong 12 months on the charts, gaining over 25%, and hitting a 15-year high of $66.80 on March 1. In the options pits, though, there's been an unusual uptick in put buying, with the stock's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) coming in at 0.73 -- in the 81st annual percentile. An unwinding of this skepticism could actually help the stock in the near term. 

Jefferies Expects a Bristol-Myers Squibb Bounce

Another drug stock Jefferies weighed in on was BMY, with the brokerage firm setting a price target of $66. This represents 15.6% upside to BMY's Wednesday close at $57.12, and territory not seen since before an August bear gap. Nevertheless, Bristol-Myers Squibb Co shares are trading slightly lower ahead of the bell, on track to add to their roughly 14% year-to-date deficit. Should upbeat analysts begin to change their tune, the stock could see additional technical trouble. Currently, eight of 13 brokerages maintain a "buy" or better rating, leaving the door wide open for downgrades. 

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.
 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners